Informacja

Drogi użytkowniku, aplikacja do prawidłowego działania wymaga obsługi JavaScript. Proszę włącz obsługę JavaScript w Twojej przeglądarce.

English (EN)·Polski (PL)·Ukraiński (UK)
Przejdź do strony domowej biblioteki Uniwersytet Ekonomiczny we Wrocławiu Link otwiera się w nowym oknie Logo biblioteki Prolib Integro - strona głównaUniwersytet Ekonomiczny we Wrocławiu

Wyszukujesz frazę ""Liu, Yunpeng"" wg kryterium: Autor

  Lista filtrów
Wyrównaj
    Wyświetlanie 1-12 z 12
    Tytuł:
    Bifunctional anti-PD-L1/TGF-βRII agent SHR-1701 in advanced solid tumors: a dose-escalation, dose-expansion, and clinical-expansion phase 1 trial.
    Autorzy:
    Liu D; Key Laboratory of Carcinogenesis and Translational Research (Ministry of Education), Early Drug Development Center, Peking University Cancer Hospital & Institute, Beijing, China.
    Zhou J; Key Laboratory of Carcinogenesis and Translational Research (Ministry of Education), Department of Gastrointestinal Oncology, Peking University Cancer Hospital & Institute, Fu-Cheng Road 52, Hai-Dian District, Beijing, 100142, China.
    Wang Y; Oncology, West China Hospital, Sichuan University, Chengdu, China.
    Li M; Oncology Department, The First Affiliated Hospital of Zhengzhou University, Zhengzhou, China.
    Jiang H; Department of Medical Oncology, First Affiliated Hospital, College of Medicine, Zhejiang University, Hangzhou, China.
    Liu Y; Medical Oncology, The First Hospital of China Medical University, Shenyang, China.
    Yin X; Department of Gastroenterology, Hunan Cancer Hospital, Changsha, China.
    Ge M; Head and Neck Surgery, Zhejiang Provincial People's Hospital, Hangzhou, China.
    Xiang X; Oncology Department, The First Affiliated Hospital of Nanchang University, Nanchang, China.
    Ying J; Hepatobiliary Pancreatic Gastroenterology, Zhejiang Cancer Hospital, Hangzhou, China.
    Huang J; Urinary Surgery, Sun Yat-sen Memorial Hospital, Sun Yat-sen University, Guangzhou, China.
    Zhang YQ; Ward 2, Department of Gastroenterology, Harbin Medical University Cancer Hospital, Harbin, China.
    Cheng Y; Oncology Department, Jilin Cancer Hospital, Changchun, China.
    Huang Z; Otolaryngology Head and Neck Surgery Center, Beijing Tongren Hospital, Beijing, China.
    Yuan X; Oncology Department, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, China.
    Han W; Urology Surgery, Hunan Cancer Hospital (The Affiliated Cancer Hospital of Xiangya School of Medicine, Central South University), Changsha, China.
    Yan D; Oncology Department, Beijing Luhe Hospital, Capital Medical University, Beijing, China.
    Wang X; Oncology Department, Henan Key Laboratory of Cancer Epigenetics, Cancer Hospital, The First Affiliated Hospital, College of Clinical Medicine, Medical College of Henan University of Science and Technology, Luoyang, China.
    Liu P; Clinical Research & Development, Jiangsu Hengrui Pharmaceuticals Co., Ltd, Shanghai, China.
    Wang L; Clinical Research & Development, Jiangsu Hengrui Pharmaceuticals Co., Ltd, Shanghai, China.
    Zhang X; Clinical Research & Development, Jiangsu Hengrui Pharmaceuticals Co., Ltd, Shanghai, China.
    Luo S; Department of Gastroenterology, Henan Tumor Hospital, Dongming Road 127, Jinshui District, Zhengzhou, 450003, China. .
    Liu T; Medical Oncology, Zhongshan Hospital Fudan University, Fenglin Road 180, Xuhui District, Shanghai, 200032, China. liu..
    Shen L; Key Laboratory of Carcinogenesis and Translational Research (Ministry of Education), Department of Gastrointestinal Oncology, Peking University Cancer Hospital & Institute, Fu-Cheng Road 52, Hai-Dian District, Beijing, 100142, China. .
    Pokaż więcej
    Źródło:
    BMC medicine [BMC Med] 2022 Oct 25; Vol. 20 (1), pp. 408. Date of Electronic Publication: 2022 Oct 25.
    Typ publikacji:
    Clinical Trial, Phase I; Journal Article; Research Support, Non-U.S. Gov't
    MeSH Terms:
    Stomach Neoplasms*
    Humans ; gamma-Glutamyltransferase/therapeutic use ; Programmed Cell Death 1 Receptor ; Antibodies, Monoclonal/therapeutic use ; Aspartate Aminotransferases/therapeutic use ; Transforming Growth Factor beta/therapeutic use ; Receptors, Transforming Growth Factor beta/therapeutic use
    Czasopismo naukowe
    Pełny tekst  Link otwiera się w nowym oknie Pełny tekstSzczegóły
    Tytuł:
    Construction of an immune-related gene signature to predict survival and treatment outcome in gastric cancer.
    Autorzy:
    Zhang S; Department of Medical Oncology, the First Hospital of China Medical University, Shenyang, China.; Key Laboratory of Anticancer Drugs and Biotherapy of Liaoning Province, the First Hospital of China Medical University, Shenyang, China.; Liaoning Province Clinical Research Center for Cancer, Shenyang, China.; Key Laboratory of Precision Diagnosis and Treatment of Gastrointestinal Tumors, Ministry of Education, Shenyang, China.
    Li Z; Department of Medical Oncology, the First Hospital of China Medical University, Shenyang, China.; Key Laboratory of Anticancer Drugs and Biotherapy of Liaoning Province, the First Hospital of China Medical University, Shenyang, China.; Liaoning Province Clinical Research Center for Cancer, Shenyang, China.; Key Laboratory of Precision Diagnosis and Treatment of Gastrointestinal Tumors, Ministry of Education, Shenyang, China.
    Dong H; Department of Medical Oncology, the First Hospital of China Medical University, Shenyang, China.; Key Laboratory of Anticancer Drugs and Biotherapy of Liaoning Province, the First Hospital of China Medical University, Shenyang, China.; Liaoning Province Clinical Research Center for Cancer, Shenyang, China.; Key Laboratory of Precision Diagnosis and Treatment of Gastrointestinal Tumors, Ministry of Education, Shenyang, China.
    Wu P; Department of Medical Oncology, the First Hospital of China Medical University, Shenyang, China.; Key Laboratory of Anticancer Drugs and Biotherapy of Liaoning Province, the First Hospital of China Medical University, Shenyang, China.; Liaoning Province Clinical Research Center for Cancer, Shenyang, China.; Key Laboratory of Precision Diagnosis and Treatment of Gastrointestinal Tumors, Ministry of Education, Shenyang, China.
    Liu Y; Department of Medical Oncology, the First Hospital of China Medical University, Shenyang, China.; Key Laboratory of Anticancer Drugs and Biotherapy of Liaoning Province, the First Hospital of China Medical University, Shenyang, China.; Liaoning Province Clinical Research Center for Cancer, Shenyang, China.; Key Laboratory of Precision Diagnosis and Treatment of Gastrointestinal Tumors, Ministry of Education, Shenyang, China.
    Guo T; Department of Medical Oncology, the First Hospital of China Medical University, Shenyang, China.; Key Laboratory of Anticancer Drugs and Biotherapy of Liaoning Province, the First Hospital of China Medical University, Shenyang, China.; Liaoning Province Clinical Research Center for Cancer, Shenyang, China.; Key Laboratory of Precision Diagnosis and Treatment of Gastrointestinal Tumors, Ministry of Education, Shenyang, China.
    Li C; Department of Medical Oncology, the First Hospital of China Medical University, Shenyang, China.; Key Laboratory of Anticancer Drugs and Biotherapy of Liaoning Province, the First Hospital of China Medical University, Shenyang, China.; Liaoning Province Clinical Research Center for Cancer, Shenyang, China.; Key Laboratory of Precision Diagnosis and Treatment of Gastrointestinal Tumors, Ministry of Education, Shenyang, China.
    Wang S; Department of Medical Oncology, the First Hospital of China Medical University, Shenyang, China.; Key Laboratory of Anticancer Drugs and Biotherapy of Liaoning Province, the First Hospital of China Medical University, Shenyang, China.; Liaoning Province Clinical Research Center for Cancer, Shenyang, China.; Key Laboratory of Precision Diagnosis and Treatment of Gastrointestinal Tumors, Ministry of Education, Shenyang, China.
    Qu X; Department of Medical Oncology, the First Hospital of China Medical University, Shenyang, China.; Key Laboratory of Anticancer Drugs and Biotherapy of Liaoning Province, the First Hospital of China Medical University, Shenyang, China.; Liaoning Province Clinical Research Center for Cancer, Shenyang, China.; Key Laboratory of Precision Diagnosis and Treatment of Gastrointestinal Tumors, Ministry of Education, Shenyang, China.
    Liu Y; Department of Medical Oncology, the First Hospital of China Medical University, Shenyang, China.; Key Laboratory of Anticancer Drugs and Biotherapy of Liaoning Province, the First Hospital of China Medical University, Shenyang, China.; Liaoning Province Clinical Research Center for Cancer, Shenyang, China.; Key Laboratory of Precision Diagnosis and Treatment of Gastrointestinal Tumors, Ministry of Education, Shenyang, China.
    Che X; Department of Medical Oncology, the First Hospital of China Medical University, Shenyang, China.; Key Laboratory of Anticancer Drugs and Biotherapy of Liaoning Province, the First Hospital of China Medical University, Shenyang, China.; Liaoning Province Clinical Research Center for Cancer, Shenyang, China.; Key Laboratory of Precision Diagnosis and Treatment of Gastrointestinal Tumors, Ministry of Education, Shenyang, China.
    Xu L; Department of Medical Oncology, the First Hospital of China Medical University, Shenyang, China.; Key Laboratory of Anticancer Drugs and Biotherapy of Liaoning Province, the First Hospital of China Medical University, Shenyang, China.; Liaoning Province Clinical Research Center for Cancer, Shenyang, China.; Key Laboratory of Precision Diagnosis and Treatment of Gastrointestinal Tumors, Ministry of Education, Shenyang, China.
    Pokaż więcej
    Źródło:
    Science progress [Sci Prog] 2021 Jan-Mar; Vol. 104 (1), pp. 36850421997286.
    Typ publikacji:
    Journal Article; Research Support, Non-U.S. Gov't
    MeSH Terms:
    Stomach Neoplasms*/genetics
    Stomach Neoplasms*/therapy
    Biomarkers, Tumor/genetics ; Gene Expression Regulation, Neoplastic ; Humans ; Prognosis ; Treatment Outcome ; Tumor Microenvironment/genetics
    Czasopismo naukowe
    Pełny tekst  Link otwiera się w nowym oknie Pełny tekstSzczegóły
    Tytuł:
    TNPO2 operates downstream of DYNC1I1 and promotes gastric cancer cell proliferation and inhibits apoptosis.
    Autorzy:
    Gong L; Department of Medical Oncology, The First Hospital of China Medical University, Shenyang, China.; Key Laboratory of Anticancer Drugs and Biotherapy of Liaoning Province, The First Hospital of China Medical University, Shenyang, China.
    Wen T; Department of Medical Oncology, The First Hospital of China Medical University, Shenyang, China.; Key Laboratory of Anticancer Drugs and Biotherapy of Liaoning Province, The First Hospital of China Medical University, Shenyang, China.
    Li Z; Department of Medical Oncology, The First Hospital of China Medical University, Shenyang, China.; Key Laboratory of Anticancer Drugs and Biotherapy of Liaoning Province, The First Hospital of China Medical University, Shenyang, China.
    Wang Y; Department of Medical Oncology, The First Hospital of China Medical University, Shenyang, China.; Key Laboratory of Anticancer Drugs and Biotherapy of Liaoning Province, The First Hospital of China Medical University, Shenyang, China.
    Wang J; Department of Medical Oncology, The First Hospital of China Medical University, Shenyang, China.; Key Laboratory of Anticancer Drugs and Biotherapy of Liaoning Province, The First Hospital of China Medical University, Shenyang, China.
    Che X; Department of Medical Oncology, The First Hospital of China Medical University, Shenyang, China.; Key Laboratory of Anticancer Drugs and Biotherapy of Liaoning Province, The First Hospital of China Medical University, Shenyang, China.
    Liu Y; Department of Medical Oncology, The First Hospital of China Medical University, Shenyang, China.; Key Laboratory of Anticancer Drugs and Biotherapy of Liaoning Province, The First Hospital of China Medical University, Shenyang, China.
    Qu X; Department of Medical Oncology, The First Hospital of China Medical University, Shenyang, China.; Key Laboratory of Anticancer Drugs and Biotherapy of Liaoning Province, The First Hospital of China Medical University, Shenyang, China.
    Pokaż więcej
    Źródło:
    Cancer medicine [Cancer Med] 2019 Dec; Vol. 8 (17), pp. 7299-7312. Date of Electronic Publication: 2019 Oct 11.
    Typ publikacji:
    Journal Article; Research Support, Non-U.S. Gov't
    MeSH Terms:
    Cell Nucleus/*metabolism
    Cytoplasmic Dyneins/*metabolism
    Stomach Neoplasms/*pathology
    beta Karyopherins/*metabolism
    Acetylation ; Active Transport, Cell Nucleus ; Apoptosis/genetics ; Cell Line, Tumor ; Cell Proliferation/genetics ; Cyclin-Dependent Kinase Inhibitor p21/metabolism ; E1A-Associated p300 Protein ; Gene Expression Profiling ; Gene Expression Regulation, Neoplastic ; Histones/metabolism ; Humans ; Promoter Regions, Genetic/genetics ; Sp1 Transcription Factor/metabolism ; Up-Regulation ; beta Karyopherins/genetics
    Czasopismo naukowe
    Pełny tekst  Link otwiera się w nowym oknie Pełny tekstSzczegóły
    Tytuł:
    CXCL9/10/11, a regulator of PD-L1 expression in gastric cancer.
    Autorzy:
    Zhang C; Department of Medical Oncology, the First Hospital of China Medical University, NO.155, North Nanjing Street, Heping District, Shenyang, 110001, China.; Department of Geratology, the First Hospital of China Medical University, Shenyang, Liaoning Province, China.
    Li Z; Department of Medical Oncology, the First Hospital of China Medical University, NO.155, North Nanjing Street, Heping District, Shenyang, 110001, China.
    Xu L; Department of Medical Oncology, the First Hospital of China Medical University, NO.155, North Nanjing Street, Heping District, Shenyang, 110001, China.
    Che X; Department of Medical Oncology, the First Hospital of China Medical University, NO.155, North Nanjing Street, Heping District, Shenyang, 110001, China.
    Wen T; Department of Medical Oncology, the First Hospital of China Medical University, NO.155, North Nanjing Street, Heping District, Shenyang, 110001, China.
    Fan Y; Department of Medical Oncology, the First Hospital of China Medical University, NO.155, North Nanjing Street, Heping District, Shenyang, 110001, China.
    Li C; Department of Medical Oncology, the First Hospital of China Medical University, NO.155, North Nanjing Street, Heping District, Shenyang, 110001, China.
    Wang S; Department of Medical Oncology, the First Hospital of China Medical University, NO.155, North Nanjing Street, Heping District, Shenyang, 110001, China.
    Cheng Y; Department of Medical Oncology, the First Hospital of China Medical University, NO.155, North Nanjing Street, Heping District, Shenyang, 110001, China.
    Wang X; Department of Medical Oncology, the First Hospital of China Medical University, NO.155, North Nanjing Street, Heping District, Shenyang, 110001, China.
    Qu X; Department of Medical Oncology, the First Hospital of China Medical University, NO.155, North Nanjing Street, Heping District, Shenyang, 110001, China. .
    Liu Y; Department of Medical Oncology, the First Hospital of China Medical University, NO.155, North Nanjing Street, Heping District, Shenyang, 110001, China. .
    Pokaż więcej
    Źródło:
    BMC cancer [BMC Cancer] 2018 Apr 24; Vol. 18 (1), pp. 462. Date of Electronic Publication: 2018 Apr 24.
    Typ publikacji:
    Journal Article; Research Support, Non-U.S. Gov't
    MeSH Terms:
    Gene Expression Regulation, Neoplastic*
    B7-H1 Antigen/*genetics
    Chemokines, CXC/*metabolism
    Stomach Neoplasms/*genetics
    Stomach Neoplasms/*metabolism
    B7-H1 Antigen/metabolism ; Biomarkers ; Cell Line, Tumor ; Chemokine CXCL10/metabolism ; Chemokine CXCL11/metabolism ; Chemokine CXCL9/metabolism ; Computational Biology/methods ; Humans ; Immunohistochemistry ; Molecular Sequence Annotation ; Neoplasm Staging ; Phosphatidylinositol 3-Kinases/metabolism ; Proto-Oncogene Proteins c-akt/metabolism ; Receptors, CXCR3/metabolism ; STAT3 Transcription Factor/metabolism ; Signal Transduction ; Stomach Neoplasms/pathology
    Czasopismo naukowe
    Pełny tekst  Link otwiera się w nowym oknieSzczegóły
    Tytuł:
    Ubiquitin ligase Cbl-b represses IGF-I-induced epithelial mesenchymal transition via ZEB2 and microRNA-200c regulation in gastric cancer cells.
    Autorzy:
    Li H
    Xu L
    Li C
    Zhao L
    Ma Y
    Zheng H
    Li Z
    Zhang Y
    Wang R
    Liu Y; Department of Medical Oncology, the First Hospital of China Medical University, NO,155, North Nanjing Street, Heping District, Shenyang 110001, China. .
    Qu X
    Pokaż więcej
    Źródło:
    Molecular cancer [Mol Cancer] 2014 Jun 02; Vol. 13, pp. 136. Date of Electronic Publication: 2014 Jun 02.
    Typ publikacji:
    Journal Article; Research Support, Non-U.S. Gov't
    MeSH Terms:
    Gene Expression Regulation, Neoplastic*
    Adaptor Proteins, Signal Transducing/*genetics
    Adenocarcinoma/*genetics
    Homeodomain Proteins/*genetics
    Insulin-Like Growth Factor I/*metabolism
    MicroRNAs/*genetics
    Proto-Oncogene Proteins c-cbl/*genetics
    Repressor Proteins/*genetics
    Stomach Neoplasms/*genetics
    Adaptor Proteins, Signal Transducing/antagonists & inhibitors ; Adaptor Proteins, Signal Transducing/metabolism ; Adenocarcinoma/metabolism ; Adenocarcinoma/pathology ; Aged ; Cell Line, Tumor ; Epithelial-Mesenchymal Transition/drug effects ; Female ; Homeodomain Proteins/metabolism ; Humans ; Insulin-Like Growth Factor I/pharmacology ; Lymphatic Metastasis ; Male ; MicroRNAs/metabolism ; Middle Aged ; Mitogen-Activated Protein Kinase 3/antagonists & inhibitors ; Mitogen-Activated Protein Kinase 3/genetics ; Mitogen-Activated Protein Kinase 3/metabolism ; Neoplasm Staging ; Protein Kinase Inhibitors/pharmacology ; Proto-Oncogene Proteins c-akt/antagonists & inhibitors ; Proto-Oncogene Proteins c-akt/genetics ; Proto-Oncogene Proteins c-akt/metabolism ; Proto-Oncogene Proteins c-cbl/antagonists & inhibitors ; Proto-Oncogene Proteins c-cbl/metabolism ; RNA, Small Interfering/genetics ; RNA, Small Interfering/metabolism ; Repressor Proteins/metabolism ; Signal Transduction ; Stomach Neoplasms/metabolism ; Stomach Neoplasms/pathology ; Zinc Finger E-box Binding Homeobox 2
    Czasopismo naukowe
    Pełny tekst  Link otwiera się w nowym oknieSzczegóły
    Tytuł:
    Interferon-α enhances 5'-deoxy-5-fluorouridine-induced apoptosis by ERK-dependant upregulation of thymidine phosphorylase.
    Autorzy:
    Zhu Y; Department of Medical Oncology, The First Hospital of China Medical University, Shenyang, Liaoning 110001, China.
    Xu L
    Fan Y
    Li C
    Zhang Y
    Zheng H
    Hou K
    Qu X
    Liu Y
    Pokaż więcej
    Źródło:
    BioMed research international [Biomed Res Int] 2013; Vol. 2013, pp. 132793. Date of Electronic Publication: 2013 Aug 20.
    Typ publikacji:
    Journal Article; Research Support, Non-U.S. Gov't
    MeSH Terms:
    Interferon-alpha/*metabolism
    Orotic Acid/*analogs & derivatives
    Stomach Neoplasms/*drug therapy
    Thymidine Phosphorylase/*metabolism
    Apoptosis/drug effects ; Capecitabine ; Cell Line, Tumor ; Cell Survival/drug effects ; Deoxycytidine/analogs & derivatives ; Deoxycytidine/metabolism ; Drug Synergism ; Fluorouracil/analogs & derivatives ; Fluorouracil/metabolism ; Gene Expression Regulation, Neoplastic/drug effects ; Humans ; Interferon-alpha/administration & dosage ; MAP Kinase Signaling System/drug effects ; Orotic Acid/administration & dosage ; Orotic Acid/metabolism ; RNA, Small Interfering ; Stomach Neoplasms/metabolism ; Stomach Neoplasms/pathology ; Thymidine Phosphorylase/antagonists & inhibitors ; Up-Regulation/drug effects
    Czasopismo naukowe
    Pełny tekst  Link otwiera się w nowym oknieSzczegóły
    Tytuł:
    β-Elemene-induced autophagy protects human gastric cancer cells from undergoing apoptosis.
    Autorzy:
    Liu J; Department of Medical Oncology, the First Hospital of China Medical University, Shenyang, PR China.
    Zhang Y
    Qu J
    Xu L
    Hou K
    Zhang J
    Qu X
    Liu Y
    Pokaż więcej
    Źródło:
    BMC cancer [BMC Cancer] 2011 May 20; Vol. 11, pp. 183. Date of Electronic Publication: 2011 May 20.
    Typ publikacji:
    Journal Article; Research Support, Non-U.S. Gov't
    MeSH Terms:
    Antineoplastic Agents/*pharmacology
    Apoptosis/*drug effects
    Autophagy/*drug effects
    Plant Extracts/*pharmacology
    Sesquiterpenes/*pharmacology
    Stomach Neoplasms/*physiopathology
    Cell Line, Tumor ; Cell Survival/drug effects ; Humans ; Phosphoinositide-3 Kinase Inhibitors ; Proto-Oncogene Proteins c-akt/antagonists & inhibitors ; Signal Transduction/drug effects ; TOR Serine-Threonine Kinases/antagonists & inhibitors
    Czasopismo naukowe
    Pełny tekst  Link otwiera się w nowym oknieSzczegóły
      Wyświetlanie 1-12 z 12

      Ta witryna wykorzystuje pliki cookies do przechowywania informacji na Twoim komputerze. Pliki cookies stosujemy w celu świadczenia usług na najwyższym poziomie, w tym w sposób dostosowany do indywidualnych potrzeb. Korzystanie z witryny bez zmiany ustawień dotyczących cookies oznacza, że będą one zamieszczane w Twoim komputerze. W każdym momencie możesz dokonać zmiany ustawień dotyczących cookies